TechPipeline logo
Magnifying glass icon
By format
Intellectual Property

Expert Strategies for Patenting and Licensing Early-Stage Drug Discoveries

Share
Print
Bookmark

What’s included

Access to the on-demand video with closed captions and presentation materials.

This program will explore the criteria for patentability, including the patenting of salts, solvates, polymorphs and prodrugs as well as drug repurposing

$197.00

Topics discussed include:

  • What can be patented?
  • Criteria for patenting drug discoveries
  • What data is needed and when is it due by?
  • Assuring novelty and anticipating invalidity challenges
  • Strategies for maximizing protection of your discoveries
  • Patents and repurposed drugs
  • Methods for attracting licensees
  • De-risking for greater marketability
  • How stage of discovery affects licensing terms

Universities and academic institutions are devoting tens of millions of research dollars toward drug discovery activity with no sign of a slowdown, and biopharma companies are increasingly relying on academia to fill their pipelines. Some universities have established their own drug development programs to de-risk their innovations and take them further toward commercialization, but for most schools the cost and risk involved is too high, and the development timeline is too long.

The most common commercialization approach is to file a patent application on an early-stage compound or drug candidate, claiming the novel and inventive aspects of the discovery, and then seek to license the early-stage asset to a commercial partner for further development.

Though it’s the more common pathway for universities and their TTOs, it’s far from a routine exercise, and rushing the process can be detrimental – if not catastrophic. Without a firm understanding of the criteria for patentability, essential claims language, data requirements, and how sponsored research and research partnerships come into play, your entire investment and your researchers’ years of hard work could go up in the smoke of invalidity challenges or licensee disinterest.

That’s why we’ve teamed up with Lisa Mueller, a patent attorney with deep experience in biopharma patent law and licensing, for this critically important program.

Ms. Mueller will explore in detail patent strategies in academic drug discovery. Specifically, the criteria for patentability, including the patenting of salts, solvates, polymorphs and prodrugs as well as drug repurposing.

Program Leaders

Patent attorney Casimir Jones

What’s included

Access to the on-demand video with closed captions and presentation materials.

This program will explore the criteria for patentability, including the patenting of salts, solvates, polymorphs and prodrugs as well as drug repurposing

$197.00

Already a subscriber? Log in

Be an “Insider”

Purchase our live and on-demand webinars individually or subscribe to TechPipeline resources at the Pro or Insider level. Subscribers enjoy free, unlimited access to our extensive collection of webinars and a lot more.

Explore our Subscriptions page to find the right subscription plan for you and your team.
Subscribe